Caladrix is a CNS-focused biotechnology company pioneering disease-modifying therapeutics for Alzheimer’s and related tauopathies. Founded in Palo Alto in 2025, our mission is to harness the brain’s intrinsic clearance pathways—starting with ABCC1, a genetically validated efflux transporter that exports neurotoxic substrates such as amyloid-beta and inflammatory mediators.
Our lead candidate, C-001, is an orally available small molecule designed to activate ABCC1. Unlike monoclonal antibody therapies, C-001 avoids ARIA risk, eliminates the need for infusion clinics, and directly restores the brain’s natural protein homeostasis. Preclinical efficacy, translational biomarker validation, and a successful human PoC study underpin our clinical development strategy.
Caladrix’s Phase 1 trial begins in H1 2026. A 300-patient Phase 2 is slated for 2027. Our pipeline includes candidates for frontotemporal dementia and other tauopathies, as well as modified-release formulations to ensure scalability and adherence.
With a strong IP estate, world-class collaborators, and a scientific team comprising Clarivate’s Highly Cited researchers, Caladrix is positioned to lead the next generation of non-immunologic neurodegenerative therapies.
Palo Alto (HQ) | Melbourne (Clinical Trials) | Hamburg (R&D)
Partner with us: bd@caladrix.bio | General: info@caladrix.bio
Company Details
- Employees
- 4
- Founded
- -
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.caladrix.bio
Caladrix Questions
Caladrix's website is http://www.caladrix.bio
Caladrix's LinkedIn profile is https://www.linkedin.com/company/caladrix
Caladrix has
4 employees.
View email and phone details for 4
employees at Caladrix.
Caladrix's industry is
Biotechnology Research
Caladrix's top competitors are
Sciberg,
Deploy Medical,
Ariax Bio,
Xpd Direct Inc.,
Catalyst Consulting,
Formoe - Forschungsforum Mobilitätsökonomik,
Propel Careers,
Otter Craft Distilling,
Ostenkurve | Coach45,
Immungenetics Ag.
Caladrix's categories are Biotechnology Research
Caladrix's founding year is 2025
